Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best low priced biotech stocks to invest in. Wells Fargo cut the price target on Nurix Therapeutics, Inc. (NASDAQ:NRIX) to $28 from $29 on April 9, maintaining an Overweight rating on the shares and stating that although management is continuing execution on bexdeg’s chronic lymphocytic leukemia trials with some modest updates expected at EHA, Wells believes bexdeg’s opportunity in immunology and inflammation remains underappreciated. The firm also stated that it sees data from ONC’s BTKdeg BGB-16673 for chronic spontaneous urticaria in the first half of 2026 as a potential upside catalyst.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) also received a rating update from Stifel on April 8, with the firm bringing the price target on the stock down to $34 from $35 while maintaining a Buy rating on the shares. The rating update came after the company reported a GAAP net loss wider than the firm’s and consensus estimates, which was driven primarily by the recognition of lower-than-expected collaborative revenue.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes innovative small molecules and antibody therapies as a novel treatment approach for inflammatory conditions, cancer, and other challenging diseases.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.